Abstract:Cancer cells evolve to be refractory to the intrinsic programmed cell death mechanisms, which ensure cellular tissue homeostasis in physiological conditions. Chemotherapy using cytotoxic drugs seeks to eliminate cancer cells but spare non-cancerous host cells by exploring a likely subtle difference between malignant and benign cells. Presumably, chemotherapy agents achieve efficacy by triggering programmed cell death machineries in cancer cells. Currently, many major solid tumors are treated with chemotherapy composed of a combination of platinum agents and taxanes. Platinum agents, largely cis-platin, carboplatin, and oxaliplatin, are DNA damaging agents that covalently form DNA addicts, triggering DNA repair response pathways. Taxanes, including paclitaxel, docetaxel, and cabazitaxel, are microtubule stabilizing drugs which are often very effective in purging cancer cells in clinical settings. Generally, it is thought that the stabilization of microtubules by taxanes leads to mitotic arrest, mitotic catastrophe, and the triggering of apoptotic programmed cell death. However, the precise mechanism(s) of how mitotic arrest and catastrophe activate the caspase pathway has not been established. Here, we briefly review literature on the involvement of potential cell death mechanisms in cancer therapy. These include the classical caspase-mediated apoptotic programmed cell death, necroptosis mediated by MLKL, and pore forming mechanisms in immune cells, etc. In particular, we discuss a newly recognized mechanism of cell death in taxane-treatment of cancer cells that involves micronucleation and the irreversible rupture of the nuclear membrane. Since cancer cells are commonly retarded in responding to programmed cell death signaling, stabilized microtubule bundle-induced micronucleation and nuclear membrane rupture, rather than triggering apoptosis, may be a key mechanism accounting for the success of taxanes as anti-cancer agents.

Antimetabolites: established cancer therapy

Cellular Responses to Platinum-Based Anticancer Drugs and UVC: Role of p53 and Implications for Cancer Therapy

Combination therapies induce cancer cell death through the integrated stress response and disturbed pyrimidine metabolism

Cell death in cancer chemotherapy using taxanes

Molecular Insight into the Apoptotic Mechanism of Cancer Cells: An Explicative Review

Molecular Mechanisms of Chemoresistance and Cytotoxicity Associated with Platinum Drugs

Anti-Apoptotic Mechanisms of Drug Resistance in Cancer

Molecular Mechanisms of Radiation-Induced Cancer Cell Death: A Primer

Cellular response to chemoradiotherapy, radiotherapy and chemotherapy in two colorectal cancer cell lines

An overview of targeted cancer therapy

Mechanisms of cancer cell killing by metformin: a review on different cell death pathways

Cell death mechanisms of plant-derived anticancer drugs: beyond apoptosis

Splicing DNA Damage Adaptations for the Management of Cancer Cells

Molecular features that predict the response to antimetabolite chemotherapies

Cell Metabolism and DNA Repair Pathways: Implications for Cancer Therapy

Dying of Stress: Chemotherapy, Radiotherapy, and Small-Molecule Inhibitors in Immunogenic Cell Death and Immunogenic Modulation

Preclinical Characteristics of Cytarabine, Gemcitabine, Fludarabine and Cladribine: Relevance for Clinical Studies

Modulation of apoptosis signaling pathways and cell cycle regulation.

An overview of chemotoxicity and radiation toxicity in cancer therapy

Cytotoxic autophagy in cancer therapy

DNA Adducts in Cancer Chemotherapy